Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Khaldoon Alaswad, M.D., FSCAI, right, during a chronic total occlusion (CTO) case in his lab at Henry Ford Hospital, Detroit. He is presenting in several SCAI 2019 sessions.  SCAI 2019 late breaking sessions, SCAI featured research sessions.

Khaldoon Alaswad, M.D., FSCAI, right, during a chronic total occlusion (CTO) case in his lab at Henry Ford Hospital, Detroit. He is presenting in several SCAI 2019 sessions.  

Feature | SCAI | May 08, 2019
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019

May 2, 2019 — Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation...

Women With Coronary Artery Wall Thickness at Risk for Heart Disease
News | Womens Cardiovascular Health | April 25, 2019

April 25, 2019  – The thickness of the coronary artery wall as measured by...

 UTHealth Research Finds Telemedicine Stroke Patients Receive Consistent Care 24/7
News | Stroke | April 24, 2019

April 24, 2019 — Stroke patients examined...

People With Heart Disease at Risk When Pharmacies Close
News | Antiplatelet and Anticoagulation Therapies | April 24, 2019

April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people...

Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019

April 23, 2019 – Determining which elderly ...

ProxiCor Extracellular Matrix Reduces Complications, Readmissions Following Pericardial Reconstruction
News | Stem Cell Therapies | April 19, 2019

April 19, 2019 — Aziyo Biologics Inc. announced the publication of results from its landmark RECON study in the...

Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019

April 18, 2019 — A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a...

HonorHealth Research Institute Launches SynIVUS-DAPT Study
News | Antiplatelet and Anticoagulation Therapies | April 16, 2019

April 16, 2019 — HonorHealth Research Institute announced the first patients have been enrolled in the...

Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019

April 15, 2019 — Despite national guidelines indicating...

Providing Follow-Up Care After Heart Attack Helps Reduce Readmissions, Deaths
News | Cath Lab | April 09, 2019

April 9, 2019 — A program designed to help ...

Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019

April 5, 2019 — Three years ago this week, Abiomed's Impella...

 Evolut Low Risk Trial compared the minimally invasive Evolut transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in characteristically younger, healthier aortic stenosis patients. The randomized trial, which met its primary non-inferiority endpoint of all-cause mortality or disabling stroke at two years compared to surgery (5.3 vs. 6.7 percent; posterior probability of non-inferiority >0.999), was presented at the American College of Cardiology (ACC) 2019 meeting
News | Heart Valve Technology | April 03, 2019

April 3, 2019 – The ACC.19 late-breaking landmark Evolut Low Risk Trial compared the minimally invasive Evolut...

Overlay Init